NasdaqGM:QTRX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$2.0b

Last Updated

2021/08/03 23:51 UTC

Data Sources

Company Financials +

Executive Summary

Quanterix Corporation, a life sciences company, develops and markets digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. More Details


Snowflake Analysis

Excellent balance sheet and overvalued.


Similar Companies

Share Price & News

How has Quanterix's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: QTRX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: QTRX's weekly volatility (10%) has been stable over the past year.


Market Performance


7 Day Return

4.9%

QTRX

3.0%

US Life Sciences

0.9%

US Market


1 Year Return

64.0%

QTRX

42.8%

US Life Sciences

34.7%

US Market

Return vs Industry: QTRX exceeded the US Life Sciences industry which returned 40.9% over the past year.

Return vs Market: QTRX exceeded the US Market which returned 34.4% over the past year.


Shareholder returns

QTRXIndustryMarket
7 Day4.9%3.0%0.9%
30 Day-7.1%4.6%0.2%
90 Day2.6%15.2%4.7%
1 Year64.0%64.0%43.0%42.8%36.8%34.7%
3 Year265.7%265.7%114.8%113.7%62.5%52.4%
5 Yearn/a235.6%231.7%123.1%98.4%

Long-Term Price Volatility Vs. Market

How volatile is Quanterix's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Quanterix undervalued compared to its fair value and its price relative to the market?

4.17x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: QTRX ($54.13) is trading above our estimate of fair value ($7.41)

Significantly Below Fair Value: QTRX is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: QTRX is unprofitable, so we can't compare its PE Ratio to the US Life Sciences industry average.

PE vs Market: QTRX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate QTRX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: QTRX is good value based on its PB Ratio (4.2x) compared to the US Life Sciences industry average (6x).


Future Growth

How is Quanterix forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

42.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: QTRX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: QTRX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: QTRX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: QTRX's revenue (18.7% per year) is forecast to grow faster than the US market (9.2% per year).

High Growth Revenue: QTRX's revenue (18.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: QTRX is forecast to be unprofitable in 3 years.


Past Performance

How has Quanterix performed over the past 5 years?

-6.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: QTRX is currently unprofitable.

Growing Profit Margin: QTRX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: QTRX is unprofitable, and losses have increased over the past 5 years at a rate of 6% per year.

Accelerating Growth: Unable to compare QTRX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: QTRX is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (51.4%).


Return on Equity

High ROE: QTRX has a negative Return on Equity (-6.37%), as it is currently unprofitable.


Financial Health

How is Quanterix's financial position?


Financial Position Analysis

Short Term Liabilities: QTRX's short term assets ($482.4M) exceed its short term liabilities ($36.5M).

Long Term Liabilities: QTRX's short term assets ($482.4M) exceed its long term liabilities ($24.7M).


Debt to Equity History and Analysis

Debt Level: QTRX's debt to equity ratio (1.6%) is considered satisfactory.

Reducing Debt: QTRX had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: QTRX has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if QTRX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Quanterix current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate QTRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate QTRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if QTRX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if QTRX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of QTRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.8yrs

Average management tenure


CEO

E. Hrusovsky (59 yo)

6.58yrs

Tenure

US$3,520,397

Compensation

Mr. E. Kevin Hrusovsky has been Independent Chairman of the Board at 908 Devices Inc. since September 2020. He has been Chairman at Quanterix Corporation since June 10, 2014 and has been its Chief Executiv...


CEO Compensation Analysis

Compensation vs Market: E.'s total compensation ($USD3.52M) is about average for companies of similar size in the US market ($USD3.71M).

Compensation vs Earnings: E.'s compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: QTRX's management team is considered experienced (3.8 years average tenure).


Board Members

Experienced Board: QTRX's board of directors are considered experienced (7.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: QTRX insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 28.3%.


Top Shareholders

Company Information

Quanterix Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Quanterix Corporation
  • Ticker: QTRX
  • Exchange: NasdaqGM
  • Founded: 2007
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.967b
  • Shares outstanding: 36.34m
  • Website: https://www.quanterix.com

Number of Employees


Location

  • Quanterix Corporation
  • Building 1
  • 900 Middlesex Turnpike
  • Billerica
  • Massachusetts
  • 1821
  • United States

Listings


Biography

Quanterix Corporation, a life sciences company, develops and markets digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Mi...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/08/03 23:51
End of Day Share Price2021/08/03 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.